enterprise

American International Group Inc. Has $6.16 Million Stake in Axon Enterprise, Inc. (NASDAQ:AXON) – Defense World



American International Group Inc. cut its position in shares of Axon Enterprise, Inc. (NASDAQ:AXONFree Report) by 1.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 19,697 shares of the biotechnology company’s stock after selling 227 shares during the quarter. American International Group Inc.’s holdings in Axon Enterprise were worth $6,163,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. ING Groep NV lifted its position in shares of Axon Enterprise by 9.3% in the fourth quarter. ING Groep NV now owns 9,643 shares of the biotechnology company’s stock worth $2,491,000 after purchasing an additional 821 shares in the last quarter. Avantax Advisory Services Inc. boosted its stake in shares of Axon Enterprise by 0.8% during the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after buying an additional 40 shares during the last quarter. Vaughan Nelson Investment Management L.P. grew its holdings in shares of Axon Enterprise by 18.4% in the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 104,587 shares of the biotechnology company’s stock valued at $27,019,000 after acquiring an additional 16,230 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Axon Enterprise in the first quarter valued at about $931,000. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Axon Enterprise by 14.8% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock worth $53,307,000 after acquiring an additional 22,013 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Readers Also Like:  Chart of the week: Outlook for US corporate earnings challenging - UBS

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $310.59 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.91 and a quick ratio of 2.55. The firm has a market cap of $23.44 billion, a price-to-earnings ratio of 90.82, a P/E/G ratio of 7.00 and a beta of 0.95. The stock’s fifty day moving average price is $294.49 and its two-hundred day moving average price is $291.73. Axon Enterprise, Inc. has a one year low of $175.37 and a one year high of $329.87.

Axon Enterprise (NASDAQ:AXONGet Free Report) last released its quarterly earnings results on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The business had revenue of $460.74 million for the quarter, compared to the consensus estimate of $441.57 million. During the same period in the prior year, the company posted $0.51 earnings per share. Axon Enterprise’s revenue was up 34.3% compared to the same quarter last year. On average, equities analysts forecast that Axon Enterprise, Inc. will post 2.35 EPS for the current year.

Insider Transactions at Axon Enterprise

In related news, Director Julie A. Cullivan sold 993 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $281.72, for a total value of $279,747.96. Following the completion of the sale, the director now directly owns 4,553 shares in the company, valued at $1,282,671.16. The sale was disclosed in a filing with the SEC, which is available at this link. In other Axon Enterprise news, President Joshua Isner sold 44,000 shares of the firm’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $309.96, for a total value of $13,638,240.00. Following the transaction, the president now directly owns 275,843 shares of the company’s stock, valued at approximately $85,500,296.28. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Julie A. Cullivan sold 993 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $281.72, for a total transaction of $279,747.96. Following the sale, the director now directly owns 4,553 shares of the company’s stock, valued at approximately $1,282,671.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 89,447 shares of company stock valued at $27,684,677. 6.10% of the stock is currently owned by company insiders.

Readers Also Like:  5 top streamers team up to launch creator-led Fortnite experience

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AXON. William Blair restated an “outperform” rating on shares of Axon Enterprise in a research note on Wednesday, April 24th. JPMorgan Chase & Co. raised their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “overweight” rating in a research note on Thursday, April 11th. Morgan Stanley upped their price target on shares of Axon Enterprise from $285.00 to $310.00 and gave the stock an “equal weight” rating in a research report on Friday, April 26th. Jefferies Financial Group initiated coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 price objective on the stock. Finally, Barclays raised their target price on shares of Axon Enterprise from $308.00 to $381.00 and gave the company an “overweight” rating in a research note on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, Axon Enterprise presently has an average rating of “Moderate Buy” and a consensus target price of $342.54.

Get Our Latest Report on Axon Enterprise

Axon Enterprise Profile

(Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Readers Also Like:  Nintendo’s winter, PlayStation’s fall, Xbox’s MasterCard | Kaser Focus

Further Reading

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXONFree Report).

Institutional Ownership by Quarter for Axon Enterprise (NASDAQ:AXON)



Receive News & Ratings for Axon Enterprise Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axon Enterprise and related companies with MarketBeat.com’s FREE daily email newsletter.



READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.